
Quarterly report 2025-Q3
added 11-12-2025
Pulmonx Corporation Cash Flow 2011-2026 | LUNG
Annual Cash Flow Pulmonx Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-31.5 M | -37.6 M | -45.1 M | -41.4 M | -30.6 M | -20.8 M | -18.4 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
1.1 M | 1.4 M | 1.4 M | 700 K | 300 K | 200 K | 100 K | - | - | - | - | - | - | - |
Accounts Payables |
3.83 M | 1.5 M | 1.76 M | 1.58 M | 1.47 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
13.1 M | 12.1 M | 8.68 M | 6.56 M | 4.23 M | - | - | - | - | - | - | - | - | - |
Total Inventories |
16.9 M | 16.7 M | 14.6 M | 16.3 M | 10.7 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Pulmonx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -13.2 M | - | - | - | -11.8 M | - | - | - | -12.6 M | - | -35.3 M | -24.6 M | -15 M | - | -30.7 M | -22.4 M | -9.67 M | - | -23.4 M | -17.5 M | -9.85 M | - | -17.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
300 K | 300 K | 300 K | - | 300 K | 300 K | 300 K | - | 400 K | 300 K | 300 K | - | 300 K | 300 K | 300 K | - | 200 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
6.42 M | 6.56 M | 4.28 M | 3.83 M | 4.58 M | 3.18 M | 3.12 M | 1.5 M | 3.19 M | 2.38 M | 2.89 M | 1.76 M | 2.65 M | 2.6 M | 2.8 M | 1.58 M | 4.43 M | 2.16 M | 1.83 M | 1.47 M | 1.47 M | 1.47 M | 1.47 M | 2.68 M | 2.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
13.8 M | 15.9 M | 14 M | 13.1 M | 11.7 M | 11.1 M | 10.5 M | 12.1 M | 10.1 M | 8.94 M | 8.17 M | 8.68 M | 7.22 M | 7.52 M | 6.81 M | 6.56 M | 6.92 M | 6.88 M | 5.12 M | 4.23 M | 4.23 M | 4.23 M | 4.23 M | 5.51 M | 5.51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
16.2 M | 16.2 M | 16.8 M | 16.9 M | 17 M | 17 M | 17.2 M | 16.7 M | 16.1 M | 15.6 M | 15.6 M | 14.6 M | 15.6 M | 19.2 M | 18.3 M | 16.3 M | 15 M | 13.4 M | 11.9 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 5.61 M | 5.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Pulmonx Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AxoGen
AXGN
|
$ 31.65 | -5.55 % | $ 1.4 B | ||
|
Abiomed
ABMD
|
- | - | $ 17.2 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 9.76 | 1.99 % | $ 701 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Apyx Medical Corporation
APYX
|
$ 3.92 | 12.33 % | $ 136 M | ||
|
Alphatec Holdings
ATEC
|
$ 17.97 | -20.68 % | $ 2.57 B | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Bio-Rad Laboratories
BIO
|
$ 322.91 | -0.16 % | $ 9.11 B | ||
|
Bruker Corporation
BRKR
|
$ 53.33 | -2.07 % | $ 7.95 K | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
$ 95.53 | -2.13 % | $ 141 B | ||
|
EDAP TMS S.A.
EDAP
|
$ 4.1 | 11.41 % | $ 153 M | ||
|
Abbott Laboratories
ABT
|
$ 124.29 | -1.27 % | $ 216 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
CONMED Corporation
CNMD
|
$ 43.45 | 1.31 % | $ 1.34 B | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 13.09 | -3.61 % | $ 1.01 B | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Electromed
ELMD
|
$ 28.66 | -0.49 % | $ 242 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.49 | 29.56 % | $ 24 M | ||
|
InMode Ltd.
INMD
|
$ 14.49 | 0.35 % | $ 1.15 B | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
$ 171.78 | -0.58 % | $ 12.9 B | ||
|
Accuray Incorporated
ARAY
|
$ 0.88 | -0.46 % | $ 90.4 M | ||
|
IRadimed Corporation
IRMD
|
$ 97.57 | -1.39 % | $ 1.24 B | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 20.12 | 9.89 % | $ 464 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
$ 15.66 | 4.96 % | $ 423 M | ||
|
FONAR Corporation
FONR
|
$ 18.6 | 0.27 % | $ 122 M | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
$ 91.33 | -3.28 % | $ 12.4 B | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Myomo
MYO
|
$ 0.99 | 0.29 % | $ 6.98 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 66.18 | -3.17 % | $ 1.86 B |